The MASCC risk score combined with the mean CRP value successfully identifies patients with febrile neutropenia and hematological malignancies and a high risk of death.

No abstract

Our findings raise the need to carefully evaluate patients with metastatic cancer, in progression, and with impaired ECOG to define the relevance of cancer treatment during the pandemic, consider the risk/benefit of the interventions, and establish clear and complete communication with the patients and their families about the risk of complications. There is also the importance of offering additional support to patients with low income and residence in rural areas so that they can have more support during cancer treatment.

The relative frequency of the non-Hodgkin lymphoma (NHL) subtypes varies around the world. The objective of this study was to describe the general features of patients with lymphoma in Colombia. A total of 819 patients with a new diagnosis of lymphoma were included. Nighty-nine (12 %) of them had Hodgkin lymphoma (HL) and 720 (88 %) had NHL. Most cases had advanced stage disease at presentation (63.6 %). Diffuse large B cell lymphoma (DLBCL) was the most frequent diagnosis; it was seen in 40 % of patients with NHL and in 35 % of patients in the whole series. Overall survival rates at 3 years were 77 % for HL and follicular lymphoma, 54 % for DLBCL, and 45 % for T cell lymphomas. In conclusion, the distribution of specific NHL subtypes is similar to what has been reported previously in other tropical countries.

Introducción: el cáncer de pulmón representa una de las patologías oncológicas más frecuentes, con una incidencia del 11,6% y una mortalidad del 18,4%1,2. Durante los últimos años han surgido nuevas tecnologías en el tratamiento de este tipo de cáncer que han impactado positivamente la supervivencia de los pacientes3 . Como alternativa a una guía de práctica clínica, los consensos de expertos son una herramienta para generar documentos a fin de orientar y unificar la práctica médica. Métodos: se llevó a cabo el segundo consenso formal de expertos constituido por 17 oncólogos de la Asociación Colombiana de Hematología y Oncología de las principales ciudades e instituciones del país. Se realizó en cuatro momentos: donde se calificaron preguntas estructuradas por el grupo desarrollador que al final fueron consensuadas en una reunión presencial (nominal). Resultados: se construyeron y calificaron 35 preguntas sobre el tratamiento del cáncer de pulmón metastásico (estadio IV), con sus respectivas sugerencias basadas en la experticia y evidencia disponible reconocidas nacional e internacionalmente, teniendo en cuenta el contexto y regulación del sistema de salud colombiano.